Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19892365 | 0.72 | NCF1 (0.43) | ACHEHRH3CHRM5ADRA2C | |
| SCHEMBL25754649 | 0.71 | ALDH1A1 (0.40) | HRH3 | |
| SCHEMBL17552000 | 0.69 | HRH3 (0.48) | HRH3 | |
| SCHEMBL25754561 | 0.69 | SIGMAR1 (0.41) | — | |
| SCHEMBL7738333 | 0.69 | ACHE (0.44) | ACHECHRM5ADRA2C | |
| SCHEMBL7738185 | 0.68 | HSD11B1 (0.47) | ACHEHRH3CHRM5ADRA2C | |
| SCHEMBL12569115 | 0.68 | CHRM2 (0.46) | ACHEHRH3CHRM5ADRA2C | |
| SCHEMBL25754631 | 0.68 | ALDH1A1 (0.40) | — | |
| SCHEMBL8363126 | 0.67 | NCF1 (0.52) | ACHEHRH3CHRM5ADRA2C | |
| SCHEMBL25754621 | 0.67 | HRH3 (0.33) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | UCHL3, UBE2L3, ADAM33 | ACHE 1382/4885HRH3 1596/4885CHRM5 4717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.